The Experts below are selected from a list of 39 Experts worldwide ranked by ideXlab platform
Henri Magdelenat - One of the best experts on this subject based on the ideXlab platform.
-
EORTC Receptor Study Group Report Steroid Receptor Distribution in 47 892 Breast Cancers. A Collaborative Study of 7 European Laboratories S. Romain, C. Lain6 Bidron, P.M. Martin, H. Magdelenat on behalf of the EORTC Receptor Study Group
1995Co-Authors: Daniel Den Hoed, Lambert Skoog, Bo Nordenskjöld, Mårten Fernö, Henri MagdelenatAbstract:Seven laboratories of the EORTC Receptor Study Group reported the distribution of oestrogen (ER) and progesterone Receptors (PR) routinely assayed in breast cancer cytosols. A low interlaboratory variability was demonstrated for the median values, and for the frequency of positive tumours as measured by enzyme immunoassay (EIA). Larger variations were found for the frequency of positive tumours, as measured by radioligand binding assaly (RLA). They are probably due to differences in the cut-off levels and in the sensitivity of the assay. Analysis of the variability over time clearly demonstrated that the ER-EIA values initially increased compared with RLA. A possible source of variations could be the calibration drift in the ER-EIA kit. In conclusion, quality assessment of steroid Receptors should be monitored by comparison of both common standards and distributions routinely obtained in each laboratory. In-house analysis over time is also essential for reagent survey.
-
Steroid Receptor distribution in 47,892 breast cancers. A collaborative Study of 7 European laboratories. The EORTC Receptor Study Group.
European Journal of Cancer, 1995Co-Authors: Sylvie Romain, Lainé Bidron C, Pierre-marie Martin, Henri MagdelenatAbstract:Seven laboratories of the EORTC Receptor Study Group reported the distribution of oestrogen (ER) and progesterone Receptors (PR) routinely assayed in breast cancer cytosols. A low interlaboratory variability was demonstrated for the median values, and for the frequency of positive tumours as measured by enzyme immunoassay (EIA). Larger variations were found for the frequency of positive tumours, as measured by radioligand binding assay (RLA). They are probably due to differences in the cut-off levels and in the sensitivity of the assay. Analysis of the variability over time clearly demonstrated that the ER-EIA values initially increased compared with RLA. A possible source of variations could be the calibration drift in the ER-EIA kit. In conclusion, quality assessment of steroid Receptors should be monitored by comparison of both common standards and distributions routinely obtained in each laboratory. In-house analysis over time is also essential for reagent survey.
Piotr Ponikowski - One of the best experts on this subject based on the ideXlab platform.
-
Heart Failure Therapeutics on the Basis of a Biased Ligand of the Angiotensin-2 Type 1 Receptor: Rationale and Design of the BLAST-AHF Study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure)
Jacc-Heart Failure, 2015Co-Authors: G. Michael Felker, Javed Butler, Sean P. Collins, Gad Cotter, Beth A. Davison, Justin A. Ezekowitz, Gerasimos Filippatos, Phillip D. Levy, Marco Metra, Piotr PonikowskiAbstract:Abstract The BLAST-AHF (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure) Study is designed to test the efficacy and safety of TRV027, a novel biased ligand of the angiotensin-2 type 1 Receptor, in patients with acute heart failure (AHF). AHF remains a major public health problem, and no currently-available therapies have been shown to favorably affect outcomes. TRV027 is a novel biased ligand of the angiotensin-2 type 1 Receptor that antagonizes angiotensin-stimulated G-protein activation while stimulating β-arrestin. In animal models, these effects reduce afterload while increasing cardiac performance and maintaining stroke volume. In initial human studies, TRV027 appears to be hemodynamically active primarily in patients with activation of the renin-angiotensin-aldosterone system, a potentially attractive profile for an AHF therapeutic. BLAST-AHF is an international prospective, randomized, phase IIb, dose-ranging Study that will randomize up to 500 AHF patients with systolic blood pressure ≥120 mm Hg and ≤200 mm Hg within 24 h of initial presentation to 1 of 3 doses of intravenous TRV027 (1, 5, or 25 mg/h) or matching placebo (1:1:1:1) for at least 48 h and up to 96 h. The primary endpoint is a composite of 5 clinical endpoints (dyspnea, worsening heart failure, length of hospital stay, 30-day rehospitalization, and 30-day mortality) combined using an average z-score. Secondary endpoints will include the assessment of dyspnea and change in amino-terminal pro–B-type natriuretic peptide. The BLAST-AHF Study will assess the efficacy and safety of a novel biased ligand of the angiotensin-2 type 1 Receptor in AHF.
Sylvie Romain - One of the best experts on this subject based on the ideXlab platform.
-
Steroid Receptor distribution in 47,892 breast cancers. A collaborative Study of 7 European laboratories. The EORTC Receptor Study Group.
European Journal of Cancer, 1995Co-Authors: Sylvie Romain, Lainé Bidron C, Pierre-marie Martin, Henri MagdelenatAbstract:Seven laboratories of the EORTC Receptor Study Group reported the distribution of oestrogen (ER) and progesterone Receptors (PR) routinely assayed in breast cancer cytosols. A low interlaboratory variability was demonstrated for the median values, and for the frequency of positive tumours as measured by enzyme immunoassay (EIA). Larger variations were found for the frequency of positive tumours, as measured by radioligand binding assay (RLA). They are probably due to differences in the cut-off levels and in the sensitivity of the assay. Analysis of the variability over time clearly demonstrated that the ER-EIA values initially increased compared with RLA. A possible source of variations could be the calibration drift in the ER-EIA kit. In conclusion, quality assessment of steroid Receptors should be monitored by comparison of both common standards and distributions routinely obtained in each laboratory. In-house analysis over time is also essential for reagent survey.
Daniel Den Hoed - One of the best experts on this subject based on the ideXlab platform.
-
EORTC Receptor Study Group Report Steroid Receptor Distribution in 47 892 Breast Cancers. A Collaborative Study of 7 European Laboratories S. Romain, C. Lain6 Bidron, P.M. Martin, H. Magdelenat on behalf of the EORTC Receptor Study Group
1995Co-Authors: Daniel Den Hoed, Lambert Skoog, Bo Nordenskjöld, Mårten Fernö, Henri MagdelenatAbstract:Seven laboratories of the EORTC Receptor Study Group reported the distribution of oestrogen (ER) and progesterone Receptors (PR) routinely assayed in breast cancer cytosols. A low interlaboratory variability was demonstrated for the median values, and for the frequency of positive tumours as measured by enzyme immunoassay (EIA). Larger variations were found for the frequency of positive tumours, as measured by radioligand binding assaly (RLA). They are probably due to differences in the cut-off levels and in the sensitivity of the assay. Analysis of the variability over time clearly demonstrated that the ER-EIA values initially increased compared with RLA. A possible source of variations could be the calibration drift in the ER-EIA kit. In conclusion, quality assessment of steroid Receptors should be monitored by comparison of both common standards and distributions routinely obtained in each laboratory. In-house analysis over time is also essential for reagent survey.
G. Michael Felker - One of the best experts on this subject based on the ideXlab platform.
-
Heart Failure Therapeutics on the Basis of a Biased Ligand of the Angiotensin-2 Type 1 Receptor: Rationale and Design of the BLAST-AHF Study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure)
Jacc-Heart Failure, 2015Co-Authors: G. Michael Felker, Javed Butler, Sean P. Collins, Gad Cotter, Beth A. Davison, Justin A. Ezekowitz, Gerasimos Filippatos, Phillip D. Levy, Marco Metra, Piotr PonikowskiAbstract:Abstract The BLAST-AHF (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure) Study is designed to test the efficacy and safety of TRV027, a novel biased ligand of the angiotensin-2 type 1 Receptor, in patients with acute heart failure (AHF). AHF remains a major public health problem, and no currently-available therapies have been shown to favorably affect outcomes. TRV027 is a novel biased ligand of the angiotensin-2 type 1 Receptor that antagonizes angiotensin-stimulated G-protein activation while stimulating β-arrestin. In animal models, these effects reduce afterload while increasing cardiac performance and maintaining stroke volume. In initial human studies, TRV027 appears to be hemodynamically active primarily in patients with activation of the renin-angiotensin-aldosterone system, a potentially attractive profile for an AHF therapeutic. BLAST-AHF is an international prospective, randomized, phase IIb, dose-ranging Study that will randomize up to 500 AHF patients with systolic blood pressure ≥120 mm Hg and ≤200 mm Hg within 24 h of initial presentation to 1 of 3 doses of intravenous TRV027 (1, 5, or 25 mg/h) or matching placebo (1:1:1:1) for at least 48 h and up to 96 h. The primary endpoint is a composite of 5 clinical endpoints (dyspnea, worsening heart failure, length of hospital stay, 30-day rehospitalization, and 30-day mortality) combined using an average z-score. Secondary endpoints will include the assessment of dyspnea and change in amino-terminal pro–B-type natriuretic peptide. The BLAST-AHF Study will assess the efficacy and safety of a novel biased ligand of the angiotensin-2 type 1 Receptor in AHF.
